Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

Core Insights - Werewolf Therapeutics, Inc. is set to present three posters at the Society for Immunotherapy of Cancer's 40th Annual Meeting, highlighting its innovative biopharmaceutical developments aimed at stimulating the immune system for cancer treatment [1][2]. Group 1: Poster Presentations - The first poster will discuss the sequential administration of WTX-124 and mWTX-330, showcasing enhanced antitumor activity in mice with poorly immunogenic EMT6 tumors without systemic toxicity [2]. - The second poster will focus on the development of conditional T cell engagers (INDUCER™ molecules) that utilize a masking approach to minimize dose-limiting cytokine release and off-target toxicity [2]. - The third poster will provide pharmacokinetic insights into the IL-2 INDUKINE prodrug WTX-124, emphasizing real-time assessment of tumor-specific activation and immune modulation [2]. Group 2: Company Overview - Werewolf Therapeutics is pioneering the development of therapeutics designed to stimulate the immune system for treating cancer and other immune-mediated conditions, leveraging its proprietary PREDATOR® platform [3]. - The company is advancing its most clinical-stage product candidates, WTX-124 and WTX-330, which are conditionally activated Interleukin-2 and Interleukin-12 INDUKINE molecules, respectively, for solid tumor treatment [3]. - Werewolf is also developing INDUCER molecules, with the first candidate, WTX-1011, targeting STEAP1 for prostate cancer, building on positive data from its INDUKINE molecules [3].